* Endo to pay Bioniche $20 mln up-front

* Potential for additional payments of up to $110 mln

* Bioniche shares up 21.7 pct in early trade (In U.S. dollars unless noted)

TORONTO, July 10 (Reuters) - Canada's Bioniche Life Sciences Inc (BNC.TO: Quote, Profile, Research) said on Friday that Endo Pharmaceuticals (ENDP.O: Quote, Profile, Research) has licensed from Bioniche exclusive rights to develop and market its Urocidin treatment in the United States with an option for global rights.

Urocidin, a bladder cancer treatment, is currently undergoing phase III clinical testing.

Cash-strapped Bioniche said recently it was in the process of addressing short-term liquidity issues through a number of activities, including a licensing agreement for Urocidin.

"We are very excited about the potential returns to Bioniche and its shareholders following commercialization of Urocidin," Bioniche Chief Executive Graeme McRae said in a statement.

Endo will pay Bioniche an upfront cash payment of $20 million, with the potential for up to $110 million in additional payments linked to the achievement of future clinical, regulatory, and commercial milestones, the companies said in a joint statement.

Bioniche will manufacture the product and receive a transfer price for supply.